MGM Resorts: Overcoming Challenges In Segments, The Stock Is Ready To Break Out Above $60
We are moving our guidance on MGM stock from Buy to Strong Buy with a price target of $61.50 for by 2Q’22. Here’s a full investment…
Seeking Alpha
TDIV: Unobvious Tech Value Play
First Trust NASDAQ Technology Dividend Index ETF (TDIV) trounces most value ETFs I have analyzed this year. However, see why…
W. P. Carey: The Market Has It All Wrong
W. P. Carey has a multi-cylinder business model from both geographical and asset class perspectives. Read more to know why I…
Bull Trap – Commodities, Dollar, Yield, Volatility Point To Trouble
Yields and dollar likely to break out. Read more to see why I think it is prudent now to hit the pause button and sit out the…
With New Wafer-Level Burn-In Products, Aehr Test Systems Has 35% Upside Potential
Aehr Test Systems is on the right path to deliver FCF. Click here to see my DCF valuation of AEHR stock and my recommendation…
Toyota’s Lexus NX A Flag Bearer For Less Hurried Electrification Strategy With Surer Returns
Toyota carbon reduction strategy relies heavily on incremental fuel-efficiency improvements. Read more to see why I remain Bullish…
InMode: Wonderful Business With Deep Economic Moat
InMode has been successfully filling the treatment gap between plastic surgery and laser procedures. Check out why INMD stock…
Intuity Medical: IPO To Fund Commercialization Of Automatic Blood Glucose Monitoring System
Intuity Medical has filed S-1 for its IPO to raise $75 million for further commercialization. Here is a full breakdown and investment…
Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization
With cash balance of $115.7 million, Citius will likely incur a loss in the E7777 transaction. It requires an upfront payment…
SPYV: Still Attractive But Unlikely To Outperform
SPYV ETF’s current pricing suggests good, positive forward returns, but I am not expecting a reversion to outperformance out…